Lamb J C, Harris M W, McKinney J D, Birnbaum L S
Toxicol Appl Pharmacol. 1986 Jun 15;84(1):115-24. doi: 10.1016/0041-008x(86)90420-5.
The induction of cleft palate by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) administered with thyroid hormones triiodothyronine (T3) or thyroxine (T4) was investigated in C57BL/6N mice. Timed-pregnant mice were treated with vehicle, TCDD, T3, T4, TCDD plus T3, or TCDD plus T4 on Days 10 to 13 of gestation. No cleft palates were observed in any control fetuses in this study, nor have there been any cleft palates in 1193 fetuses or 154 control litters in the past 24 months. TCDD (3 micrograms/kg/day) caused about 8% cleft palates per litter, while T3 (120, 240, 480 micrograms/kg/day) and T4 (625, 1250, 2500 micrograms/kg/day) resulted in no more than 1.2% cleft palates per litter in any of the treatment groups and the incidence was not dose related. The combination of TCDD (3 micrograms/kg/day) plus T3 at 120, 240, and 480 micrograms/kg/day resulted in 15.9, 20.6, and 31.4% cleft palates per litter, respectively. TCDD plus T4 at 625, 1250 and 2500 micrograms/kg/day caused 15.1, 22.9, and 27.2% cleft palates per litter. No cleft palates were observed when large doses of T3 were given in combination with T4. These data demonstrated that coadministration of T3 or T4 with TCDD increased the incidence of cleft palate to incidences greater than expected from the separate administration of the hormones plus TCDD.
在C57BL/6N小鼠中研究了2,3,7,8-四氯二苯并对二恶英(TCDD)与甲状腺激素三碘甲状腺原氨酸(T3)或甲状腺素(T4)联合给药诱导腭裂的情况。在妊娠第10至13天,对定时怀孕的小鼠分别给予赋形剂、TCDD、T3、T4、TCDD加T3或TCDD加T4。本研究中,任何对照胎儿均未观察到腭裂,在过去24个月的1193只胎儿或154窝对照胎仔中也未出现腭裂。TCDD(3微克/千克/天)导致每窝约8%的胎儿出现腭裂,而T3(120、240、480微克/千克/天)和T4(625、1250、2500微克/千克/天)在任何治疗组中导致每窝腭裂发生率均不超过1.2%,且发生率与剂量无关。TCDD(3微克/千克/天)与120、240和480微克/千克/天的T3联合使用时,每窝腭裂发生率分别为15.9%、20.6%和31.4%。TCDD与625、1250和2500微克/千克/天的T4联合使用时,每窝腭裂发生率分别为15.1%、22.9%和27.2%。当大剂量T3与T4联合给药时,未观察到腭裂。这些数据表明,T3或T4与TCDD联合给药会使腭裂发生率增加,高于单独给予激素加TCDD时预期的发生率。